Literature DB >> 21135535

Using the WHOQOL-DIS to measure quality of life in persons with physical disabilities caused by neurodegenerative disorders.

Ramona Lucas-Carrasco1, Berta Pascual-Sedano, Ingrid Galán, Jaime Kulisevsky, Jaume Sastre-Garriga, Juana Gómez-Benito.   

Abstract

BACKGROUND/AIMS: Neurodegenerative disorders (ND) have a major impact on quality of life (QoL) and place a substantial burden on patients, their families and carers; they are the second leading cause of disability. The objective of this study was to examine QoL in persons with ND.
METHODS: A battery of subjective assessments was used, including the World Health Organization Quality of Life Questionnaire (WHOQOL-BREF) and the World Health Organization Quality of Life - Disability (WHOQOL-DIS). Psychometric properties of the WHOQOL-BREF and WHOQOL-DIS were investigated using classical psychometric methods.
RESULTS: Participants (n = 149) were recruited and interviewed at two specialized centers to obtain information on health and disability perceptions, depressive symptoms (Hospital Anxiety and Depression Scale - Depression, HADS-D), Fatigue Assessment Scale (FAS), Satisfaction with Life (SWL), generic QoL (WHOQOL-BREF, WHOQOL-DIS), specific QoL (Multiple Sclerosis Impact Scale, MSIS-29; Parkinson's Disease Questionnaire, PDQ-39) and sociodemographics. Internal consistency was acceptable, except for the WHOQOL-BREF social (0.67). Associations, using Pearson's and Spearman's rho correlations, were confirmed between WHOQOL-BREF and WHOQOL-DIS with MSIS-29, PDQ-39, HADS-D, FAS and SWL. Regarding 'known group' differences, Student's t tests showed that WHOQOL-BREF and WHOQOL-DIS scores significantly discriminated between depressed and nondepressed and those perceiving a more severe impact of the disability on their lives.
CONCLUSION: This study is the first to report on use of the WHOQOL-BREF and WHOQOL-DIS in Spanish persons with ND; they are promising useful tools in assessing persons with ND through the continuum of care, as they include important dimensions commonly omitted from other QoL measures.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 21135535     DOI: 10.1159/000321582

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  6 in total

1.  The WHO quality of life (WHOQOL) questionnaire: Spanish development and validation studies.

Authors:  Ramona Lucas-Carrasco
Journal:  Qual Life Res       Date:  2011-05-25       Impact factor: 4.147

2.  Quality of life in a German cohort of Parkinson's patients assessed with three different measures.

Authors:  M Balzer-Geldsetzer; J Klotsche; R Dodel; O Riedel
Journal:  J Neurol       Date:  2018-09-12       Impact factor: 4.849

3.  Preliminary validation study of the WHO quality of life (WHOQOL) scales for people with spinal cord injury in Mainland China.

Authors:  Feng-Shui Chang; Qi Zhang; Hai-Xia Xie; Hui-Fang Wang; Yu-Hui Yang; Ying Gao; Chuan-Wei Fu; Gang Chen; Jun Lu
Journal:  J Spinal Cord Med       Date:  2020-12-02       Impact factor: 2.040

4.  Improving Adherence Physical Activity with a Smartphone Application Based on Adults with Intellectual Disabilities (APPCOID).

Authors:  David Pérez-Cruzado; Antonio I Cuesta-Vargas
Journal:  BMC Public Health       Date:  2013-12-13       Impact factor: 3.295

5.  The role of quality of care and attitude towards disability in the relationship between severity of disability and quality of life: findings from a cross-sectional survey among people with physical disability in China.

Authors:  Qiao-Lan Zheng; Qi Tian; Chun Hao; Jing Gu; Ramona Lucas-Carrasco; Jian-Ting Tao; Zuo-Yi Liang; Xin-Lin Chen; Ji-Qian Fang; Jian-Hua Ruan; Qiu-Xiang Ai; Yuan-Tao Hao
Journal:  Health Qual Life Outcomes       Date:  2014-02-23       Impact factor: 3.186

6.  Validation of a cross-NTD toolkit for assessment of NTD-related morbidity and disability. A cross-cultural qualitative validation of study instruments in Colombia.

Authors:  Janneke Fischer; Benita Jansen; Alberto Rivera; Libardo J Gómez; Martha C Barbosa; Jorge L Bilbao; José M González; Luis Restrepo; Yesenia Vidal; Ruth M H Peters; Wim H van Brakel
Journal:  PLoS One       Date:  2019-12-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.